Aernout D van Haarst (Aernout van Haarst)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Atrial Fibrillation

Top Venues

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Sabina Paglialunga, Natacha Benrimoh, Aernout D van Haarst
Innovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies. Pharmaceutics 16 (8) (2024)
Robert M Lester, Caroline Engel, Aernout D van Haarst, Sabina Paglialunga
Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT Liability. Clinical pharmacology and therapeutics (2024)
Robert M Lester, Caroline Engel, Aernout D van Haarst, Sabina Paglialunga
Should You Run a Dedicated TQT Study? Sponsor and Regulatory Considerations on Substitution Pathways to Assess QT Liability. Clinical pharmacology and therapeutics 116 (1) (2024)
Sabina Paglialunga, Natacha Benrimoh, Aernout D van Haarst
Innovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies. Pharmaceutics 16 (8) (2024)
Aernout D van Haarst, Stephen Smith, Clare Garvin, Natacha Benrimoh, Sabina Paglialunga
Rifampin Drug-Drug-Interaction Studies: Reflections on the Nitrosamine Impurities Issue. Clinical pharmacology and therapeutics (2022)